The Pharma Data

DECEMBER 17, 2020

COVID-19 vaccine developers are faced with an ethical quandary — whether to let phase 3 trial participants become “unblinded” and to receive authorized vaccines as they become available, which could hinder the collection of meaningful trial data. Pfizer, which has received emergency approvals in the U.S.

Vaccine 52

Vaccine Trials Long-Term Care Facilities FDA 52

The Pharma Data

JANUARY 26, 2021

While the preliminary nature of Phase 2 results from COVID-19 neutralizing monoclonal antibodies may have limited acceptance of treatment, these Phase 3 data further strengthen the available evidence,” said Daniel Skovronsky, M.D., INDIANAPOLIS, Jan. Across 1,035 patients, there were 11 events (2.1 have reached record highs.

Hospitals 52

Hospitals Treatment Long-Term Care Facilities Trials 52

The Pharma Data

NOVEMBER 9, 2020

Bamlanivimab is authorized for the treatment of mild to moderate COVID-19 in adults and pediatric patients 12 years and older with a positive COVID-19 test, who are at high risk for progressing to severe COVID-19 and/or hospitalization. Sites of care will then confirm their need and AmerisourceBergen will distribute bamlanivimab overnight.

Treatment 52

Treatment FDA Hospitals Long-Term Care Facilities 52